NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
56 hedge funds and large institutions have $59.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.
14,400% more call options, than puts
Call options by funds: $145K | Put options by funds: $1K
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
21% more capital invested
Capital invested by funds: $49M → $59.3M (+$10.3M)
6% more funds holding
Funds holding: 53 → 56 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$5.75M |
| 2 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
+$1.2M |
| 3 |
GCM
Glenview Capital Management
New York
|
+$906K |
| 4 |
SCM
Sio Capital Management
New York
|
+$906K |
| 5 |
Two Sigma Investments
New York
|
+$837K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.05M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$546K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$255K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$240K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$192K |
NBSE Hedge Fund Activity: Q1 2021 in Review
56 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2021, worth a combined $59.3M — up 21% from $49M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NBSE positions and 8 closed out — a net gain of 3 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $5.75M. The largest seller was Renaissance Technologies, cutting an estimated $2.05M.
- 56 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2021, up from 53 in Q4 2020.
- Funds reported $59.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2021, up 21% quarter-over-quarter.
- 11 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +3 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2021 was Polar Asset Management Partners, an estimated $5.75M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2021 was Renaissance Technologies, an estimated $2.05M sold.
Based on aggregated 13F filings for Q1 2021.